Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic

Author(s): Rajesh Kumar, Seetha Harilal, Abdullah G. Al-Sehemi, Githa Elizabeth Mathew, Simone Carradori* and Bijo Mathew*

Volume 28, Issue 15, 2021

Published on: 02 July, 2020

Page: [2852 - 2886] Pages: 35

DOI: 10.2174/0929867327666200702151018

Price: $65

Abstract

COVID-19, a type of infection that emerged in Wuhan, has become a pandemic affecting people worldwide and is rapidly spreading and evolving. Day by day, the confirmed cases and deaths are increasing many folds. SARS-CoV-2 is a novel virus; therefore, limited data are available to curb the disease. Epidemiological approaches, such as isolation, quarantine, social distancing, lockdown, and curfew, are being employed to halt the spread of the disease. Individual and joint efforts all over the world are producing a wealth of data and information which are expected to produce therapeutic strategies against COVID-19. Current research focuses on the utilization of antiviral drugs, repurposing strategies, vaccine development, as well as basic to advanced research about the organism and the infection. The review focuses on its life cycle, targets, and possible therapeutic strategies, which can lead to further research and development of COVID-19 therapy.

Keywords: Antiviral drugs, ACE2, COVID-19, MERS-CoV, Drug repurposing, SARS-CoV-2, coronavirus, SARS-CoV, Vaccines.

« Previous Next »
[1]
Momattin, H.; Mohammed, K.; Zumla, A.; Memish, Z.A.; Al-Tawfiq, J.A. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. Int. J. Infect. Dis., 2013, 17(10), e792-e798.
[http://dx.doi.org/10.1016/j.ijid.2013.07.002] [PMID: 23993766]
[2]
Jiang, F.; Deng, L.; Zhang, L.; Cai, Y.; Cheung, C.W.; Xia, Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J. Gen. Intern. Med., 2020, 35(5), 1545-1549.
[http://dx.doi.org/10.1007/s11606-020-05762-w] [PMID: 32133578]
[3]
Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor Recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of sars coronavirus. J. Virol., 2020, 94(7), e00127-e20.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]
[4]
WHO says vaccines against novel coronavirus 18 months away, pushes global research. Available at http://www.xinhuanet.com/english/2020-02/12/c_1387778-86.htm [accessed on: May 19, 2020].
[5]
Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S.I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[6]
Liu, K.; Fang, Y-Y.; Deng, Y.; Liu, W.; Wang, M-F.; Ma, J-P.; Xiao, W.; Wang, Y-N.; Zhong, M-H.; Li, C-H.; Li, G-C.; Liu, H-G. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin. Med. J. (Engl.), 2020, 133(9), 1025-1031.
[http://dx.doi.org/10.1097/CM9.0000000000000744] [PMID: 32044814]
[7]
Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 2020, 395(10223), e30-e31.
[http://dx.doi.org/10.1016/S0140-6736(20)30304-4] [PMID: 32032529]
[8]
Carradori, S. Are there any therapeutic options currently available for Wuhan coronavirus? Antiinflamm. Antiallergy Agents Med. Chem., 2020, 19(2), 85-87.
[http://dx.doi.org/10.2174/1871523019999200228100917] [PMID: 32213152]
[9]
WHO coronavirus disease (COVID-19) dashboard. Available at https://covid19.who.int/?gclid=EAIaIQobChMI0sn- Cwoy96QIVCbaWCh0pjQ9mEAAYASAAEgJBTPD_Bw E [accessed on: May 19, 2020].
[10]
WHO Gender and COVID-19: advocacy brief, 14 May 2020. Available at https://apps.who.int/iris/handle/10665/332080 [accessed on: May 19, 2020].
[11]
UN Women Data Hub, COVID-19: Emerging gender data and why it matters. Available at https://data.unwomen.org/resources/covid-19-emerging-gender-data-and-why-it-matters [accessed on: May 19, 2020].
[12]
Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol., 2020, 92(4), 418-423.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[13]
Benvenuto, D.; Giovanetti, M.; Ciccozzi, A.; Spoto, S.; Angeletti, S.; Ciccozzi, M. The 2019-new coronavirus epidemic: evidence for virus evolution. J. Med. Virol., 2020, 92(4), 455-459.
[http://dx.doi.org/10.1002/jmv.25688] [PMID: 31994738]
[14]
Chan, J.F-W.; Kok, K-H.; Zhu, Z.; Chu, H.; To, K.K-W.; Yuan, S.; Yuen, K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 2020, 9(1), 221-236.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[15]
Hui, D.S.; Azhar, I. E.; Madani, T.A.; Ntoumi, F.; Kock, R.; Dar, O.; Ippolito, G.; Mchugh, T.D.; Memish, Z.A.; Drosten, C.; Zumla, A.; Petersen, E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis., 2020, 91, 264-266.
[http://dx.doi.org/10.1016/j.ijid.2020.01.009] [PMID: 31953166]
[16]
Zhou, P.; Yang, X-L.; Wang, X-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H-R.; Zhu, Y.; Li, B.; Huang, C-L.; Chen, H-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R-D.; Liu, M-Q.; Chen, Y.; Shen, X-R.; Wang, X.; Zheng, X-S.; Zhao, K.; Chen, Q-J.; Deng, F.; Liu, L-L.; Yan, B.; Zhan, F-X.; Wang, Y-Y.; Xiao, G-F.; Shi, Z-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798), 270-273.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[17]
Wu, F.; Zhao, S.; Yu, B.; Chen, Y-M.; Wang, W.; Song, Z-G.; Hu, Y.; Tao, Z-W.; Tian, J-H.; Pei, Y-Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798), 265-269.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[18]
Cui, J.; Li, F.; Shi, Z-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 2019, 17(3), 181-192.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[19]
Zhang, N.; Jiang, S.; Du, L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines, 2014, 13(6), 761-774.
[http://dx.doi.org/10.1586/14760584.2014.912134] [PMID: 24766432]
[20]
Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.G.; Decroly, E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res., 2020, 176104742
[http://dx.doi.org/10.1016/j.antiviral.2020.104742] [PMID: 32057769]
[21]
Xia, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; Qin, C.; Sun, F.; Shi, Z.; Zhu, Y.; Jiang, S.; Lu, L. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res., 2020, 30(4), 343-355.
[http://dx.doi.org/10.1038/s41422-020-0305-x] [PMID: 32231345]
[22]
Xia, S.; Zhu, Y.; Liu, M.; Lan, Q.; Xu, W.; Wu, Y.; Ying, T.; Liu, S.; Shi, Z.; Jiang, S.; Lu, L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol., 2020, 17(7), 765-767.
[http://dx.doi.org/10.1038/s41423-020-0374-2] [PMID: 32047258]
[23]
Yu, F.; Du, L.; Ojcius, D.M.; Pan, C.; Jiang, S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect., 2020, 22(2), 74-79.
[http://dx.doi.org/10.1016/j.micinf.2020.01.003] [PMID: 32017984]
[24]
Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K-Y.; Wang, Q.; Zhou, H.; Yan, J.; Qi, J. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, 2020, 181(4), 894-904.e9.
[http://dx.doi.org/10.1016/j.cell.2020.03.045] [PMID: 32275855]
[25]
Lan, J.; Ge, J.; Yu, J.; Shan, S.; Zhou, H.; Fan, S.; Zhang, Q.; Shi, X.; Wang, Q.; Zhang, L.; Wang, X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 2020, 581(7807), 215-220.
[http://dx.doi.org/10.1038/s41586-020-2180-5] [PMID: 32225176]
[26]
Shang, J.; Ye, G.; Shi, K.; Wan, Y.; Luo, C.; Aihara, H.; Geng, Q.; Auerbach, A.; Li, F. Structural basis of receptor recognition by SARS-CoV-2. Nature, 2020, 581(7807), 221-224.
[http://dx.doi.org/10.1038/s41586-020-2179-y] [PMID: 32225175]
[27]
Kang, S.; Yang, M.; Hong, Z.; Zhang, L.; Huang, Z.; Chen, X.; He, S.; Zhou, Z.; Zhou, Z.; Chen, Q.; Yan, Y.; Zhang, C.; Shan, H.; Chen, S. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm. Sin. B, 2020, 10(7), 1228-1238.
[http://dx.doi.org/10.1016/j.apsb.2020.04.009] [PMID: 32363136]
[28]
Neuman, B.W.; Kiss, G.; Kunding, A.H.; Bhella, D.; Baksh, M.F.; Connelly, S.; Droese, B.; Klaus, J.P.; Makino, S.; Sawicki, S.G.; Siddell, S.G.; Stamou, D.G.; Wilson, I.A.; Kuhn, P.; Buchmeier, M.J. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol., 2011, 174(1), 11-22.
[http://dx.doi.org/10.1016/j.jsb.2010.11.021] [PMID: 21130884]
[29]
Nieto-Torres, J.L.; DeDiego, M.L.; Verdiá-Báguena, C.; Jimenez-Guardeño, J.M.; Regla-Nava, J.A.; Fernandez-Delgado, R.; Castaño-Rodriguez, C.; Alcaraz, A.; Torres, J.; Aguilella, V.M.; Enjuanes, L. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog., 2014, 10(5)e1004077
[http://dx.doi.org/10.1371/journal.ppat.1004077] [PMID: 24788150]
[30]
Kim, Y.; Jedrzejczak, R.; Maltseva, N.I.; Wilamowski, M.; Endres, M.; Godzik, A.; Michalska, K.; Joachimiak, A. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci., 2020, 29(7), 1596-1605.
[http://dx.doi.org/10.1002/pro.3873] [PMID: 32304108]
[31]
Li, F.; Li, W.; Farzan, M.; Harrison, S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science, 2005, 309(5742), 1864-1868.
[http://dx.doi.org/10.1126/science.1116480] [PMID: 16166518]
[32]
de Wilde, A.H.; Snijder, E.J.; Kikkert, M.; van Hemert, M.J. Host Factors in Coronavirus Replication. In: Roles of Host Gene and Non-coding RNA Expression in Virus Infection; Tripp, R.A.; Tompkins, S.M., Eds.; Springer: New York, 2017, pp. 1-42.
[http://dx.doi.org/10.1007/82_2017_25]
[33]
Kim, D.; Lee, J-Y.; Yang, J-S.; Kim, J.W.; Kim, V.N.; Chang, H. The architecture of SARS-CoV-2 transcriptome. Cell, 2020, 181(4), 914-921.e10.
[http://dx.doi.org/10.1016/j.cell.2020.04.011] [PMID: 32330414]
[34]
Shereen, M.A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J. Adv. Res., 2020, 24, 91-98.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[35]
Sawicki, S.G.; Sawicki, D.L. Coronavirus Transcription: A Perspective. In: Coronavirus replication and reverse genetics; Enjuanes, L., Ed.; Springer: New York, 2005, Vol. 287, pp. 31-55.
[http://dx.doi.org/10.1007/3-540-26765-4_2]
[36]
Hussain, S.; Pan, J.; Chen, Y.; Yang, Y.; Xu, J.; Peng, Y.; Wu, Y.; Li, Z.; Zhu, Y.; Tien, P.; Guo, D. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J. Virol., 2005, 79(9), 5288-5295.
[http://dx.doi.org/10.1128/JVI.79.9.5288-5295.2005] [PMID: 15827143]
[37]
Perrier, A.; Bonnin, A.; Desmarets, L.; Danneels, A.; Goffard, A.; Rouillé, Y.; Dubuisson, J.; Belouzard, S. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J. Biol. Chem., 2019, 294(39), 14406-14421.
[http://dx.doi.org/10.1074/jbc.RA119.008964] [PMID: 31399512]
[38]
Guo, Y-R.; Cao, Q-D.; Hong, Z-S.; Tan, Y-Y.; Chen, S-D.; Jin, H-J.; Tan, K-S.; Wang, D-Y.; Yan, Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res., 2020, 7(1), 11.
[http://dx.doi.org/10.1186/s40779-020-00240-0] [PMID: 32169119]
[39]
Sigrist, C.J.; Bridge, A.; Le Mercier, P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res., 2020, 177104759
[http://dx.doi.org/10.1016/j.antiviral.2020.104759] [PMID: 32130973]
[40]
Alexopoulou, L.; Holt, A.C.; Medzhitov, R.; Flavell, R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 2001, 413(6857), 732-738.
[http://dx.doi.org/10.1038/35099560] [PMID: 11607032]
[41]
Wu, J.; Chen, Z.J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol., 2014, 32, 461-488.
[http://dx.doi.org/10.1146/annurev-immunol-032713-120156] [PMID: 24655297]
[42]
Wu, J.; Sun, L.; Chen, X.; Du, F.; Shi, H.; Chen, C.; Chen, Z.J. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science, 2013, 339(6121), 826-830.
[http://dx.doi.org/10.1126/science.1229963] [PMID: 23258412]
[43]
Seth, R.B.; Sun, L.; Ea, C-K.; Chen, Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 2005, 122(5), 669-682.
[http://dx.doi.org/10.1016/j.cell.2005.08.012] [PMID: 16125763]
[44]
Ishikawa, H.; Barber, G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature, 2008, 455(7213), 674-678.
[http://dx.doi.org/10.1038/nature07317] [PMID: 18724357]
[45]
Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 2010, 11(5), 373-384.
[http://dx.doi.org/10.1038/ni.1863] [PMID: 20404851]
[46]
Bisht, H.; Roberts, A.; Vogel, L.; Subbarao, K.; Moss, B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology, 2005, 334(2), 160-165.
[http://dx.doi.org/10.1016/j.virol.2005.01.042] [PMID: 15780866]
[47]
Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223), 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[48]
Chen, C.; Zhang, X.R.; Ju, Z.Y.; He, W.F. [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies]. Zhonghua Shao Shang Za Zhi, 2020, 36(6), 471-475.
[http://dx.doi.org/10.3760/cma.j.cn501120-20200224-00088] [PMID: 32114747]
[49]
Shi, Y.; Wang, Y.; Shao, C.; Huang, J.; Gan, J.; Huang, X.; Bucci, E.; Piacentini, M.; Ippolito, G.; Melino, G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ., 2020, 27(5), 1451-1454.
[http://dx.doi.org/10.1038/s41418-020-0530-3] [PMID: 32205856]
[50]
Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., 2020, 8(4), 420-422.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[51]
Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol., 2020, 20(5), 269-270.
[http://dx.doi.org/10.1038/s41577-020-0308-3] [PMID: 32273594]
[52]
Ye, Q.; Wang, B.; Mao, J. The pathogenesis and treatment of the ‘cytokine storm’ in COVID-19. J. Infect., 2020, 80(6), 607-613.
[http://dx.doi.org/10.1016/j.jinf.2020.03.037] [PMID: 32283152]
[53]
Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; Zhang, X.; Zhang, M.; Wu, S.; Song, J.; Chen, T.; Han, M.; Li, S.; Luo, X.; Zhao, J.; Ning, Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest., 2020, 130(5), 2620-2629.
[http://dx.doi.org/10.1172/JCI137244] [PMID: 32217835]
[54]
Diao, B.; Wang, C.; Tan, Y.; Chen, X.; Liu, Y.; Ning, L.; Chen, L.; Li, M.; Liu, Y.; Wang, G.; Yuan, Z.; Feng, Z.; Zhang, Y.; Wu, Y.; Chen, Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol., 2020, 11, 827.
[http://dx.doi.org/10.3389/fimmu.2020.00827] [PMID: 32425950]
[55]
Pedersen, S.F.; Ho, Y-C. SARS-CoV-2: a storm is raging. J. Clin. Invest., 2020, 130(5), 2202-2205.
[http://dx.doi.org/10.1172/JCI137647] [PMID: 32217834]
[56]
Moore, J.B.; June, C.H. Cytokine release syndrome in severe COVID-19. Science, 2020, 368(6490), 473-474.
[http://dx.doi.org/10.1126/science.abb8925] [PMID: 32303591]
[57]
Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. HLH Across Speciality Collaboration. UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, 395(10229), 1033-1034.
[http://dx.doi.org/10.1016/S0140-6736(20)30628-0] [PMID: 32192578]
[58]
Sun, P.; Lu, X.; Xu, C.; Sun, W.; Pan, B. Understanding of COVID-19 based on current evidence. J. Med. Virol., 2020, 92(6), 548-551.
[http://dx.doi.org/10.1002/jmv.25722] [PMID: 32096567]
[59]
Yeo, C.; Kaushal, S.; Yeo, D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol. Hepatol., 2020, 5(4), 335-337.
[http://dx.doi.org/10.1016/S2468-1253(20)30048-0] [PMID: 32087098]
[60]
Cai, J.; Sun, W.; Huang, J.; Gamber, M.; Wu, J.; He, G. Indirect virus transmission in cluster of covid-19 cases, Wenzhou, China, 2020. Emerg. Infect. Dis., 2020, 26(6), 1343-1345.
[http://dx.doi.org/10.3201/eid2606.200412] [PMID: 32163030]
[61]
Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D-Y.; Chen, L.; Wang, M. Presumed asymptomatic carrier transmission of COVID-19. JAMA, 2020, 323(14), 1406-1407.
[http://dx.doi.org/10.1001/jama.2020.2565] [PMID: 32083643]
[62]
Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H-L.; Peiris, M.; Wu, J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med., 2020, 382(12), 1177-1179.
[http://dx.doi.org/10.1056/NEJMc2001737] [PMID: 32074444]
[63]
van Doremalen, N.; Bushmaker, T.; Morris, D.H.; Holbrook, M.G.; Gamble, A.; Williamson, B.N.; Tamin, A.; Harcourt, J.L.; Thornburg, N.J.; Gerber, S.I.; Lloyd-Smith, J.O.; de Wit, E.; Munster, V.J. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med., 2020, 382(16), 1564-1567.
[http://dx.doi.org/10.1056/NEJMc2004973] [PMID: 32182409]
[64]
Lu, C.W.; Liu, X.F.; Jia, Z.F. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet, 2020, 395(10224)e39
[http://dx.doi.org/10.1016/S0140-6736(20)30313-5] [PMID: 32035510]
[65]
WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19) [accessed on: May 19, 2020].
[66]
CDC, Symptoms of Coronavirus, 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [accessed on: May 19, 2020].
[67]
Overview | coronavirus disease COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/ [accessed on: May 19, 2020].
[68]
Shi, H.; Han, X.; Jiang, N.; Cao, Y.; Alwalid, O.; Gu, J.; Fan, Y.; Zheng, C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect. Dis., 2020, 20(4), 425-434.
[http://dx.doi.org/10.1016/S1473-3099(20)30086-4] [PMID: 32105637]
[69]
Pan, Y.; Zhang, D.; Yang, P.; Poon, L.L.M.; Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis., 2020, 20(4), 411-412.
[http://dx.doi.org/10.1016/S1473-3099(20)30113-4] [PMID: 32105638]
[70]
Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirglmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N. Engl. J. Med., 2020, 382(10), 970-971.
[http://dx.doi.org/10.1056/NEJMc2001468] [PMID: 32003551]
[71]
Yu, P.; Zhu, J.; Zhang, Z.; Han, Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J. Infect. Dis., 2020, 221(11), 1757-1761.
[http://dx.doi.org/10.1093/infdis/jiaa077] [PMID: 32067043]
[72]
Detection of low level of COVID-19 virus in pet dog. Available at https://www.info.gov.hk/gia/general/202002/28/P2020022800013.htm [accessed on: May 19, 2020].
[73]
Almendros, A. Can companion animals become infected with Covid-19? Vet. Rec., 2020, 186(12), 388-389.
[http://dx.doi.org/10.1136/vr.m1194] [PMID: 32221002]
[74]
Pet dog tests positive for COVID-19 virus. Available at: https://www.info.gov.hk/gia/general/202003/19/P2020031900606.htm [accessed on: May 19, 2020].
[75]
Promed Post – ProMED-Mail. Available at: https://promedmail.org/ [accessed on: May 19, 2020].
[76]
Coronavirus: Belgium reaches 7,284 confirmed cases. Available at: https://www.brusselstimes.com/all-news/belgium-all-news/102984/coronavirus-belgium-reaches-7284-confirmed-cases/ [accessed on: May 19, 2020].
[77]
Pet cat tests positive for COVID-19. Available at: http://www.news.gov.hk/eng/2020/03/20200331/20200331_220128_110.html [accessed on: May 19, 2020].
[78]
James, A. A Tiger at Bronx Zoo Tests Positive for COVID-19. Available at: https://wpde.com/news/coronavirus/a-tiger-at-bronx-zoo-tests-positive-for-covid-19 [accessed on: May 19, 2020].
[79]
Leroy, E.M.; Ar Gouilh, M.; Brugère-Picoux, J. The risk of SARS-CoV-2 transmission to pets and other wild and domestic animals strongly mandates a one-health strategy to control the COVID-19 pandemic. One Health, 2020, 10100133
[http://dx.doi.org/10.1016/j.onehlt.2020.100133] [PMID: 32363229]
[80]
Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science, 2020, 368(6494), 1016-1020.
[http://dx.doi.org/10.1126/science.abb7015] [PMID: 32269068]
[81]
van den Brand, J.M.A.; Haagmans, B.L.; Leijten, L.; van Riel, D.; Martina, B.E.; Osterhaus, A.D.; Kuiken, T. Pathology of experimental SARS coronavirus infection in cats and ferrets. Vet. Pathol., 2008, 45(4), 551-562.
[http://dx.doi.org/10.1354/vp.45-4-551] [PMID: 18587105]
[82]
Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M. SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. bioRxiv, 2020. preprint.
[http://dx.doi.org/10.1101/2020.04.01.021196]
[83]
2 cats in NY become first US pets to test positive for virus. Available at: https://apnews.com/37328ab8db093b8346 [accessed on: May 19, 2020].
[84]
Halfmann, P.J.; Hatta, M.; Chiba, S.; Maemura, T.; Fan, S.; Takeda, M.; Kinoshita, N.; Hattori, S.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kawaoka, Y. Transmission of SARS-CoV-2 in domestic cats. N. Engl. J. Med., 2020, 383(6), 592-594.
[http://dx.doi.org/10.1056/nejmc2013400] [PMID: 32402157]
[85]
Wang, H.; Wang, F.; Wang, H.; Zhao, Q. Potential infectious risk from the pets carrying SARS-CoV-2. Travel Med. Infect. Dis., 2020, 35101737
[http://dx.doi.org/10.1016/j.tmaid.2020.101737] [PMID: 32380152]
[86]
Zheng, Y-Y.; Ma, Y-T.; Zhang, J-Y.; Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol., 2020, 17(5), 259-260.
[http://dx.doi.org/10.1038/s41569-020-0360-5] [PMID: 32139904]
[87]
Fang, L.; Karakiulakis, G.; Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med., 2020, 8(4)e21
[http://dx.doi.org/10.1016/S2213-2600(20)30116-8] [PMID: 32171062]
[88]
Nilsson, A.; Edner, N.; Albert, J.; Ternhag, A. Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child. Infect. Dis. (Lond.), 2020, 52(6), 419-422.
[http://dx.doi.org/10.1080/23744235.2020.1729403] [PMID: 32067542]
[89]
Mahajan, A.; Hirsch, J.A. Novel coronavirus: what neuroradiologists as citizens of the world need to know. AJNR Am. Soc. Neuroradiology, 2020, 41(4), 552-554.
[http://dx.doi.org/10.3174/ajnr.a6526] [PMID: 32198164]
[90]
Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis., 2020, 71(15), 762-768.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[91]
Monteil, V.; Kwon, H.; Prado, P.; Hagelkrüys, A.; Wimmer, R.A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Hurtado Del Pozo, C.; Prosper, F.; Romero, J.P.; Wirnsberger, G.; Zhang, H.; Slutsky, A.S.; Conder, R.; Montserrat, N.; Mirazimi, A.; Penninger, J.M. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 2020, 181(4), 905-913.e7.
[http://dx.doi.org/10.1016/j.cell.2020.04.004] [PMID: 32333836]
[92]
Zhao, B.; Ni, C.; Gao, R.; Wang, Y.; Yang, L.; Wei, J.; Lv, T.; Liang, J.; Zhang, Q.; Xu, W.; Xie, Y.; Wang, X.; Yuan, Z.; Liang, J.; Zhang, R.; Lin, X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell, 2020, 11(10), 771-775.
[http://dx.doi.org/10.1007/s13238-020-00718-6] [PMID: 32303993]
[93]
Puelles, V.G.; Lütgehetmann, M.; Lindenmeyer, M.T.; Sperhake, J.P.; Wong, M.N.; Allweiss, L.; Chilla, S.; Heinemann, A.; Wanner, N.; Liu, S.; Braun, F.; Lu, S.; Pfefferle, S.; Schröder, A.S.; Edler, C.; Gross, O.; Glatzel, M.; Wichmann, D.; Wiech, T.; Kluge, S.; Pueschel, K.; Aepfelbacher, M.; Huber, T.B. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med., 2020, 383(6), 590-592.
[http://dx.doi.org/10.1056/nejmc2011400] [PMID: 32402155]
[94]
Pan, X.W.; Xu, D.; Zhang, H.; Zhou, W.; Wang, L.H.; Cui, X.G. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med., 2020, 46(6), 1114-1116.
[http://dx.doi.org/10.1007/s00134-020-06026-1] [PMID: 32236644]
[95]
Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; Albaiu, D. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent. Sci., 2020, 6(3), 315-331.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[96]
Dong, L.; Hu, S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther., 2020, 14(1), 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[97]
De Clercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem. Asian J., 2019, 14(22), 3962-3968.
[http://dx.doi.org/10.1002/asia.201900841] [PMID: 31389664]
[98]
Sheahan, T.P.; Sims, A.C.; Leist, S.R.; Schäfer, A.; Won, J.; Brown, A.J.; Montgomery, S.A.; Hogg, A.; Babusis, D.; Clarke, M.O.; Spahn, J.E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J.Y.; Cihlar, T.; Jordan, R.; Denison, M.R.; Baric, R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun., 2020, 11(1), 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[99]
Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F.G.; Horby, P.W.; Zhang, D.; Wang, C. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 2020, 82(19), 1787-1799.
[http://dx.doi.org/10.1056/nejmoa2001282] [PMID: 32187464]
[100]
Arabi, Y.M.; Alothman, A.; Balkhy, H.H.; Al-Dawood, A.; AlJohani, S.; Al Harbi, S.; Kojan, S.; Al Jeraisy, M.; Deeb, A.M.; Assiri, A.M.; Al-Hameed, F.; AlSaedi, A.; Mandourah, Y.; Almekhlafi, G.A.; Sherbeeni, N.M.; Elzein, F.E.; Memon, J.; Taha, Y.; Almotairi, A.; Maghrabi, K.A.; Qushmaq, I.; Al Bshabshe, A.; Kharaba, A.; Shalhoub, S.; Jose, J.; Fowler, R.A.; Hayden, F.G.; Hussein, M.A. And the MIRACLE trial group. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018, 19(1), 81.
[http://dx.doi.org/10.1186/s13063-017-2427-0] [PMID: 29382391]
[101]
Chu, C.M.; Cheng, V.C.C.; Hung, I.F.N.; Wong, M.M.L.; Chan, K.H.; Chan, K.S.; Kao, R.Y.T.; Poon, L.L.M.; Wong, C.L.P.; Guan, Y.; Peiris, J.S.; Yuen, K.Y. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 2004, 59(3), 252-256.
[http://dx.doi.org/10.1136/thorax.2003.012658] [PMID: 14985565]
[102]
Chan, K.S.; Lai, S.T.; Chu, C.M.; Tsui, E.; Tam, C.Y.; Wong, M.M.; Tse, M.W.; Que, T.L.; Peiris, J.S.; Sung, J.; Wong, V.C.; Yuen, K.Y. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J., 2003, 9(6), 399-406.
[PMID: 14660806]
[103]
Li, G.; De Clercq, E. Therapeutic Options for the 2019 Novel Coronavirus (2019-NCoV). Nat. Rev. Drug Discov., 2019, 19(3), 149-150.
[http://dx.doi.org/10.1038/d41573-020-00016-0] [PMID: 32127666]
[104]
Mifsud, E.J.; Hayden, F.G.; Hurt, A.C. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res., 2019, 169104545
[http://dx.doi.org/10.1016/j.antiviral.2019.104545] [PMID: 31247246]
[105]
Maxmen, A. More than 80 clinical trials launch to test coronavirus treatments. Nature, 2020, 578(7795), 347-348.
[http://dx.doi.org/10.1038/d41586-020-00444-3] [PMID: 32071447]
[106]
Delang, L.; Abdelnabi, R.; Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res., 2018, 153, 85-94.
[http://dx.doi.org/10.1016/j.antiviral.2018.03.003] [PMID: 29524445]
[107]
Furuta, Y.; Komeno, T.; Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci., 2017, 93(7), 449-463.
[http://dx.doi.org/10.2183/pjab.93.027] [PMID: 28769016]
[108]
Kadam, R.U.; Wilson, I.A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc. Natl. Acad. Sci. USA, 2017, 114(2), 206-214.
[http://dx.doi.org/10.1073/pnas.1617020114] [PMID: 28003465]
[109]
Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N-H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[110]
Hoffmann, M.; Kleine-Weber, H.; Krüger, N.; Mueller, M.A.; Drosten, C.; Pöhlmann, S. The novel coronavirus 2019 (2019-NCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Biorxiv, preprint article.
[http://dx.doi.org/10.1101/2020.01.31.929042]
[111]
Coleman, C.M.; Sisk, J.M.; Mingo, R.M.; Nelson, E.A.; White, J.M.; Frieman, M.B. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J. Virol., 2016, 90(19), 8924-8933.
[http://dx.doi.org/10.1128/JVI.01429-16] [PMID: 27466418]
[112]
Feire, A.L.; Koss, H.; Compton, T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc. Natl. Acad. Sci. USA, 2004, 101(43), 15470-15475.
[http://dx.doi.org/10.1073/pnas.0406821101] [PMID: 15494436]
[113]
Xiao, J.; Palefsky, J.M.; Herrera, R.; Berline, J.; Tugizov, S.M. The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells. Virology, 2008, 370(2), 430-442.
[http://dx.doi.org/10.1016/j.virol.2007.09.012] [PMID: 17945327]
[114]
Wickham, T.J.; Filardo, E.J.; Cheresh, D.A.; Nemerow, G.R. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol., 1994, 127(1), 257-264.
[http://dx.doi.org/10.1083/jcb.127.1.257] [PMID: 7523420]
[115]
Hussein, H.A.; Walker, L.R.; Abdel-Raouf, U.M.; Desouky, S.A.; Montasser, A.K.M.; Akula, S.M. Beyond RGD: virus interactions with integrins. Arch. Virol., 2015, 160(11), 2669-2681.
[http://dx.doi.org/10.1007/s00705-015-2579-8] [PMID: 26321473]
[116]
Hatley, R.J.D.; Macdonald, S.J.F.; Slack, R.J.; Le, J.; Ludbrook, S.B.; Lukey, P.T. An αv-RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities. Angew. Chem. Int. Ed. Engl., 2018, 57(13), 3298-3321.
[http://dx.doi.org/10.1002/anie.201707948] [PMID: 28944552]
[117]
Kumar, R.; Harilal, S.; Gupta, S.V.; Jose, J.; Thomas Parambi, D.G.; Uddin, M.S.; Shah, M.A.; Mathew, B. Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. Eur. J. Med. Chem., 2019, 182111602
[http://dx.doi.org/10.1016/j.ejmech.2019.111602] [PMID: 31421629]
[118]
Stebbing, J.; Phelan, A.; Griffin, I.; Tucker, C.; Oechsle, O.; Smith, D.; Richardson, P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis., 2020, 20(4), 400-402.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID: 32113509]
[119]
Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[120]
Gao, J.; Tian, Z.; Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends, 2020, 14(1), 72-73.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[121]
Haładyj, E.; Sikora, M.; Felis-Giemza, A.; Olesińska, M. Antimalarials - are they effective and safe in rheumatic diseases? Reumatologia, 2018, 56(3), 164-173.
[http://dx.doi.org/10.5114/reum.2018.76904] [PMID: 30042604]
[122]
Keyaerts, E.; Li, S.; Vijgen, L.; Rysman, E.; Verbeeck, J.; Van Ranst, M.; Maes, P. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother., 2009, 53(8), 3416-3421.
[http://dx.doi.org/10.1128/AAC.01509-08] [PMID: 19506054]
[123]
Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J., 2005, 2, 69.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[124]
Savarino, A.; Boelaert, J.R.; Cassone, A.; Majori, G.; Cauda, R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect. Dis., 2003, 3(11), 722-727.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[125]
Hempelmann, E. Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol. Res., 2007, 100(4), 671-676.
[http://dx.doi.org/10.1007/s00436-006-0313-x] [PMID: 17111179]
[126]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[127]
Wolfram, J.; Ferrari, M. Clinical cancer nanomedicine. Nano Today, 2019, 25, 85-98.
[http://dx.doi.org/10.1016/j.nantod.2019.02.005] [PMID: 31360214]
[128]
Miller, S.E.; Mathiasen, S.; Bright, N.A.; Pierre, F.; Kelly, B.T.; Kladt, N.; Schauss, A.; Merrifield, C.J.; Stamou, D.; Höning, S.; Owen, D.J. CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature. Dev. Cell, 2015, 33(2), 163-175.
[http://dx.doi.org/10.1016/j.devcel.2015.03.002] [PMID: 25898166]
[129]
Hu, T.Y.; Frieman, M.; Wolfram, J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat. Nanotechnol., 2020, 15(4), 247-249.
[http://dx.doi.org/10.1038/s41565-020-0674-9] [PMID: 32203437]
[130]
Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; Liu, X.; Zhao, L.; Dong, E.; Song, C.; Zhan, S.; Lu, R.; Li, H.; Tan, W.; Liu, D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020, 71(15), 732-739.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[131]
Liu, J.; Cao, R.; Xu, M.; Wang, X.; Zhang, H.; Hu, H.; Li, Y.; Hu, Z.; Zhong, W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov., 2020, 6, 16.
[http://dx.doi.org/10.1038/s41421-020-0156-0] [PMID: 32194981]
[132]
McChesney, E.W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med., 1983, 75(1A), 11-18.
[http://dx.doi.org/10.1016/0002-9343(83)91265-2] [PMID: 6408923]
[133]
Search of COVID-19 - search details at ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results/details? cond=COVID-19 [accessed on: May 19, 2020].
[134]
Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses, 2020, 12(3), 254.
[http://dx.doi.org/10.3390/v12030254] [PMID: 32106567]
[135]
Amanat, F.; Krammer, F. SARS-CoV-2 vaccines: status report. Immunity, 2020, 52(4), 583-589.
[http://dx.doi.org/10.1016/j.immuni.2020.03.007] [PMID: 32259480]
[136]
Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med., 2020, 382(21), 1969-1973.
[http://dx.doi.org/10.1056/NEJMp2005630] [PMID: 32227757]
[137]
Diamond, M.S.; Pierson, T.C. The Challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe, 2020, 27(5), 699-703.
[http://dx.doi.org/10.1016/j.chom.2020.04.021] [PMID: 32407708]
[138]
Side effects halt use of chloroquine vs. COVID‐19. Available at: https://www.webmd.com/lung/news/20200407/side-effects-halt-use-of-chloroquine-vs-covid-19 [accessed on: May 19, 2020].
[139]
Singh, B.; Ryan, H.; Kredo, T.; Chaplin, M.; Fletcher, T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19. Cochrane Database Syst. Rev., 2020. (2), CD013587.
[http://dx.doi.org/10.1002/14651858.cd013587.pub2] [PMID: 33624299]
[140]
COVID-19: reminder of risk serious side effects with chloroquine and hydroxychloroquine. Available at: https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine [accessed on: May 19, 2020].

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy